placement at .31, page-33

re: bargain buying pbio's cabe,

yes, crystal balls or not, it's interesting how the peregrine crew usually get to buy in when they have deals to ink ... still major shareholder meetings usually result in good news. In any case, i'd have to be considered a major option holder now ... based on the previous top 20 ... i'd be hanging round the low teens i reckon .... i may not get a vote, but i get great leverage.

So is it a good decision to weigh in heavily on options during this share price weakness? let's see ... 20 months until expiry ... no time premium at current prices ... takes my average price to .12 ... all the other factors going in premiers favour ... am i missing something here? Perhaps it will be hard to offload so many ... but then again i quite fancy that prediction of a pre-open and a 40% spike on a commercial deal -- not to mention a 12 month cgt benefit already locked away on half my holding ... this has got me thinking it doesn't get any better than this. The devices appear to work well, they fill an identified market niche in a clinical, but can they sell them? I say yes. Throw in some punters returning to the biotechs .... My risk, my fault if it all goes pearshaped.